Central nervous system (CNS) diseases are often characterized by neuroinflammation, driven by the activation of microglia cells. Traditional drug development has focused on removing accumulated proteins, neglecting the therapeutic potential of targeting neuroinflammation directly. This leaves a gap in treatment options that address the inflammatory component of these diseases.

Neuro Therapia is developing oral, small molecule therapeutics designed to inhibit microglia cells and reduce neuroinflammation in the CNS. Their lead program, NTRX-07, aims to improve the brain's ability to form new connections, potentially leading to improved learning and memory. This approach offers a novel strategy for treating CNS conditions by targeting the inflammatory processes that contribute to disease progression. NTRX-07 has demonstrated a favorable safety profile and a pharmacokinetic profile consistent with preclinical studies.

Orally available small molecule formulation for convenient administration.

Selective inhibition of microglia cells to modulate neuroinflammation.

Potential to improve cognitive function by enhancing brain connectivity.

Demonstrated favorable safety profile in Phase 1b clinical trials.

Pharmacokinetic profile consistent with preclinical studies.

The primary target audience includes individuals suffering from CNS diseases characterized by neuroinflammation, such as Alzheimer's disease, and the healthcare professionals who treat them.